番茄社区app

Combination testing also tied to fewer referrals for further diagnostics

Head-to-head comparison in ALLIANCE trial favors use over dolutegravir-based combination

ANDES study shows less expensive therapy to be a "safe and well-tolerated" option

International experts advocate for accurate, timely information, while minimizing discrimination

Demonstrators used their time at the convention center to endorse the "U = U" message

Trial in Brazil offers hope for "late-presenter HIV patients"

SIMPL'HIV and NAMSAL trial data support WHO backing of dolutegravir, expert says

Functional cures now seen in 5 patients

Incidence of gonorrhea, chlamydia, and syphilis more than halved

Long-acting cabotegravir dramatically cuts estimated HIV incidence

Promising results after an unusual treatment regimen, though questions remain

IAC roundtable addresses prospects for cure, now proven to be possible

IAS past president recalls history, local HCPs debate pros and cons

Other chemotherapies fall behind in resource-limited setting